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aithersburg and Rockville, Maryland; Boston, Massachusetts; and Miami, Florida
OBJECTIVES This study examined human drug-eluting stents (DES) to determine the long-term effects of
these stents on coronary arterial healing and identified mechanisms underlying late stent
thrombosis (LST).
BACKGROUND Although DES reduce the need for repeat revascularization compared with bare-metal stents
(BMS), data suggest the window of thrombotic risk for Cypher (Cordis Corp., Miami Lakes,
Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) DES extends far beyond
that for BMS.
METHODS From a registry of 40 autopsies of DES (68 stents), 23 DES cases of 30 days duration were
compared with 25 matched autopsies of BMS implantation. Late stent thrombosis was
defined as an acute thrombus within a stent 30 days old.
RESULTS Of 23 patients with DES 30 days old, 14 had evidence of LST. Cypher and Taxus DES
showed greater delayed healing characterized by persistent fibrin deposition (fibrin score 2.3
 1.1 vs. 0.9  0.8, p  0.0001) and poorer endothelialization (55.8  26.5%) compared
with BMS (89.8  20.9, p  0.0001). Moreover, DES with LST showed more delayed
healing compared with patent DES. In 5 of 14 patients suffering LST, antiplatelet therapy
had been withdrawn. Additional procedural and pathologic risk factors for LST were: 1) local
hypersensitivity reaction; 2) ostial and/or bifurcation stenting; 3) malapposition/incomplete
apposition; 4) restenosis; and 5) strut penetration into a necrotic core.
CONCLUSIONS The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of
similar implant duration. The cause of DES LST is multifactorial with delayed healing in
combination with other clinical and procedural risk factors playing a role. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.042Cardiol 2006;48:193–202) © 2006 by the American College of Cardiology Foundation
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wtent thrombosis remains a major cause of death and
orbidity after percutaneous coronary interventions (1–4).
he pivotal clinical trials that formed the basis for approval
f drug-eluting stents (DES) have not shown an increase in
tent thrombosis compared with bare-metal stents (BMS)
5,6). However, recent publication of “real-world” patients
See page 203
eceiving DES have suggested that the window of throm-
otic risk at sites where these stents have been deployed
xtends far beyond that for BMS (7,8). Understanding the
ime course of healing in DES compared with BMS and the
athologic mechanisms underlying late stent thrombosis
LST) might more clearly delineate the time course of
hrombotic risk and redefine the optimal duration of anti-
latelet therapy.
From *CVPath, International Registry of Pathology, Gaithersburg, Maryland;
Cardiac Unit, Department of Internal Medicine, Massachusetts General Hospital,
oston, Massachusetts; ‡Miami Dade County Medical Examiner Department, Heart
adiology, Miami, Florida; and the §Interventional Cardiology Devices Branch, U.S.
ood and Drug Administration, Rockville, Maryland. Drs. Joner and Finn contrib-
ted equally to this work.s
Manuscript received January 26, 2006; revised manuscript received March 10,
006, accepted March 16, 2006.Current polymer-based sirolimus-eluting (Cypher, Cor-
is Corp., Miami Lakes, Florida) and paclitaxel-eluting
Taxus, Boston Scientific Corp., Natick, Massachusetts)
tents are the only DES approved by the U.S. Food and
rug Administration (FDA) for human use. Some pub-
ished studies of animal models with similar DES implanted
n normal arteries show a substantial impairment of arterial
ealing relative to BMS (9–13). To date, there has been no
ystematic published analysis of the long-term effects of
ES on arterial healing in humans. We examined 40
onsecutive autopsies of patients who died subsequent to
ES implantation to determine the long-term effects of
ES placement on coronary arterial healing and to identify
athologic mechanisms underlying LST.
ATERIALS AND METHODS
rom a registry of 484 human coronary stents submitted for
onsultation, 40 consecutive cases with evidence of one or more
ES were examined (3 have been previously reported) (14–
6). Of these cases, 23 (32 stents) had DES implanted for30
ays and were included in the DES study group. Clinical
istories and cardiac catheterization reports were reviewed
hen available. A total of 25 cases of BMS implantation (36tents) of patients of similar age, gender, case duration, and
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Pathology of Drug-Eluting Stents July 4, 2006:193–202rtery of implantation were blindly selected from our registry
nd formed the control BMS group. Cases with a history of
rior brachytherapy were excluded.
Stented arteries had been fixed in 10% buffered formalin,
issected off the heart, examined via radiography, and
ubmitted for plastic embedding. Arteries were sectioned 2
o 3 mm apart and stained with hematoxylin and eosin and
ovat pentachrome as previously described (17). Cases
ith histologic evidence of an acute occlusive or nonocclu-
ive mural thrombus within a coronary artery stent in place
30 days were defined as LST. Stented arteries with severe
arrowing, defined as in-stent luminal cross-sectional area
arrowing of 75% by neointimal growth, were defined as
estenosis; and those 75% area narrowing were designated
s patent stents.
orphologic and morphometric measurements. Computer-
uided morphometric measurements were performed using
PLab Spectrum software (Scanalytics Inc., Vienna, Vir-
inia) on sections from stents implanted for 30 days.
igital images were captured (4 magnification), and area
easurements included the internal elastic lamina, plaque
urden, stent area, and lumen area; stent lengths were
easured from radiographs. For calculation of in-stent
eointimal growth, fibrin deposition, and surface endothe-
ialization, stents with occlusive thrombi were excluded to
vercome biased measurements. Ordinal data for fibrin were
ollected on each stent section using a scale of 0 to 3 as
reviously reported (18). Inflammation was scored at each
tent strut using a scale from 0 to 5 (with 0 for 0 to 25
urrounding inflammatory cells, 1 for 25 to 50, 2 for 50 to
00, 3 for 100 to 150, 4 for 150 to 200, and 5 for 200
urrounding inflammatory cells). The percentage of struts
igure 1. Flow diagram illustrating cause of death in drug-eluting stents (D
Abbreviations and Acronyms
BMS bare-metal stents
DES  drug-eluting stents
FDA Food and Drug Administration
LST  late stent thrombosisajor categories depending on whether stents showed evidence of late thrombo
CD  sudden cardiac death.ith surrounding fibrin and luminal surface endothelium
as also recorded. Delayed arterial healing was defined as
ersistence of fibrin beyond 30 days. Total eosinophils were
valuated by counting the four most severely inflamed struts
er section and reported as eosinophils per strut.
tatistical analysis. Continuous variables are presented as
he mean  SD and categorical variables either as mean 
D or frequency (%). Continuous variables were first
hecked for normal distribution using Shapiro-Wilk
oodness-of-fit test and compared by Student t test for
ormally distributed or a Wilcoxon rank-sum test for
on-normally distributed variables. For comparison of rates
f LST between the DES group and the control BMS
roup, a Fisher exact test was used. A p value 0.05 was
onsidered significant. The percentage of struts covered by
ndothelial cells was plotted against the duration of implant
o derive a slope, intercept, and correlation coefficient to
etermine relationships.
ESULTS
atient characteristics. Thirty-two DES were examined
rom 23 individuals and compared with 36 matched BMS
rom 25 individuals. In patients with DES, indications for
tenting were unstable angina or acute myocardial infarction
n  5 patients for Cypher, n  7 for Taxus), stable angina
n  5 for Cypher, n  5 for Taxus), or restenosis (n  1
or Cypher). The location of the stents was: left anterior
escending/left diagonal (Cypher, n  10 stents; Taxus, n
6; BMS, n  13); right coronary artery/posterior de-
cending artery (Cypher, n  4; Taxus, n  5; BMS, n 
2); and left circumflex/left obtuse marginal (Cypher, n 
; Taxus, n  4; BMS, n  11).
rocedural outcome. At the time of coronary intervention,
ll patients had angiographically successful stent deploy-
ent with one DES placed in 15 patients, two DES in 7
atients, and three DES in 1 patient. Mean stent length for
ES was 32.1  17.3 mm (range 8 to 76 mm; median 25
m, 75% 35 mm). Ostial/bifurcation stenting was per-
ormed in three cases (left circumflex/obtuse marginal bi-
patients with stents in place 30 days. These cases are divided into threeES)
sis, were patent, or were restenotic. AMI  acute myocardial infarction;
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July 4, 2006:193–202 Pathology of Drug-Eluting Stentsurcation stenting, crush technique; left anterior descend-
ng/diagonal ostial stenting; and left anterior descending at
he take-off of left circumflex [ostial stenting]), and all three
ases showed occlusive thrombi.
Thirty-six BMS were examined from 25 individuals
mean age 61  9 years) with one BMS placed in 18
atients, two BMS in 4 patients, three BMS in 2 patients,
nd four BMS in 1 patient. Mean stent length for BMS was
0.2  11.9 mm (range 8 to 42 mm; median 18 mm, 75%
33 mm). Ostial/bifurcation stenting was performed in two
ases (left anterior descending/diagonal bifurcation stenting,
-stenting technique; and left circumflex/obtuse marginal
stial stenting), and both died secondary to restenosis
ithout evidence of thrombosis.
ntiplatelet therapy. During catheterization procedures,
spirin and clopidogrel were administered to all patients; 17
f 23 patients were being continued on an antiplatelet
egimen at the time of death. In five cases, it was confirmed
hat patients were not receiving clopidogrel or aspirin at the
igure 2. Line chart comparing the percentage of endothelialization in dr
able 1. Morphometric Characteristics of DES Versus BMS 3
Group
Mean Duration
(days)
IEL Area
(mm2)
Plaque Area
(mm2)
ES (n  32) 223  253 12.9  5.3 8.1  4.2
MS (n  36) 299  360 12.5  5.1 6.3  3.3
Value ns* ns* ns
Group
Inflammation
Score
No. of
Eosinophils/Strut†
ES (n  32) 1.7  1.5 5.6  11.1
MS (n  36) 1.3  0.8 0.6  2.3
Value ns* 0.01*
Chi-square; †stents with occlusive thrombi were excluded for neointimal area meas
BMS  bare-metal stent; DES  drug-eluting stent; IEL  internal elastic lumote that DES (solid line) consistently show less endothelialization compared w
ES are not fully endothelialized, whereas BMS are completely covered by 6 time of death. In one case the antiplatelet therapy was
nknown at the time of death. Of the 17 patients who could
e confirmed to be on antiplatelet therapy, 14 were main-
ained on dual antiplatelet therapy with aspirin and clopi-
ogrel. An additional two patients were receiving clopi-
ogrel monotherapy, and one patient was on aspirin only.
auses of death. Thirteen of the 14 DES cases of LST
ied of cardiac causes (Fig. 1). The cause of death was either
otal thrombotic occlusion of the stent or subtotal occlusion
ith distal embolization leading to acute myocardial infarc-
ion or sudden cardiac death. Seven DES cases had patent
tents, and none died of stent-related complications. Two
ES cases had in-stent restenosis and died of acute myo-
ardial infarction or sudden cardiac death. Two of the 25
MS patients died of LST. Eighteen BMS cases had patent
tents, and no patients died of stent-related complications
15 patients had a cardiac cause of death and 3 had a
oncardiac cause of death). Five patients with BMS im-
lants had in-stent restenosis and died secondary to stent
ting stents (DES) versus bare-metal stents (BMS) as a function of time.
ys
tent Length
(mm)
Stent Area
(mm2)
Neointimal Area†
(mm2) % Stenosis†
32.1  17.3 6.7  2.7 2.8  1.1 51.4  22.4
20.2  11.9 7.7  3.5 4.9  3.0 66.5  22.0
0.01* ns* 0.0003* 0.01*
Fibrin Score†
% Struts
With Fibrin†
% Struts
Endothelialized†
2.3  1.1 49.3  30.8 55.8  26.5
0.9  0.8 22.3  17.8 89.8  20.9
0.0001* 0.0005* 0.0001*
ts (n  11 excluded for DES, 0 for BMS).ug-elu0 Da
Sith BMS (dashed line) regardless of time point. Even beyond 40 months
o 7 months.
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Pathology of Drug-Eluting Stents July 4, 2006:193–202elated acute myocardial infarction (three cases) or sudden
ardiac death (two cases).
ST (>30 days). Of 23 DES cases, 14 (61%) had stent
hrombosis, and of the 25 cases of BMS included as
ontrols, 2 (8%) had LST (p 0.0001). Both cases of BMS
ST also had evidence of in-stent restenosis. The rate of
ST in the control BMS group is similar to that previously
eported from our registry of BMS (19).
omparison of DES and BMS implants. Stent length in
ES was greater than in BMS (32.1  17.3 vs. 20.2 
1.9, p  0.01) (Table 1). The DES had significantly less
n-stent neointimal growth compared with BMS (neointi-
al area 2.9  1.1 mm2 vs. 4.9  3.0 mm2, p  0.005; %
tenosis 54.4  23.6% vs. 66.5  22.0%, p  0.05).
lthough the extent of overall inflammation was not sig-
ificantly different in the two groups, eosinophils surround-
ng struts were more frequent in DES compared with BMS
5.6 11.1 vs. 0.6 2.3 per strut, p 0.01). The DES also
howed significantly higher fibrin scores (2.3  1.1 vs. 0.9
0.8, p  0.0001) and percentage of struts surrounded by
able 2. Morphometric Characteristics of DES With Late (30
Group
Mean
Duration
(days)
IEL
Area
(mm2)
Plaque
Area
(mm2)
hrombosis (n  20) 197  139 13.1  4.6 9.6  4.0
o thrombosis (n  12) 181  135 11.0  5.8 5.8  3.5
Value ns* ns 0.008
Chi-square.
Abbreviations as in Table 1.
able 3. Pathological Mechanisms of Stent Thrombosis 30 Da
ge (yrs),
Gender
PCI
Indication
Artery
Stented Stents
N
ST Associated With Delayed Healing
5, M Angina LAD Taxus
8, M UA LCX Cypher
1, M Angina PDA Cypher
ST Associated With Delayed He
7, F Angina LAD Taxus
ST Associated With Delayed Healin
7, M† AMI LAD, LCX Cypher
8, F‡ Angina LOM Cypher, Taxus
2, M§ AMI LAD Taxus
ST Associated With Delayed Healing
2, M Angina RCA Cypher
8, F¶ Angina LAD Taxus
ST Associated With De
5, M AMI RCA Cypher
0, F AMI LAD Taxus
Associated with aneurysm and malapposition; †ostial stenting LAD/LCX; ‡bifurca
iagonal; ¶incomplete apposition.AMI acute myocardial infarction; LAD left anterior descending artery; LCX left
CA  right coronary artery; SCD  sudden cardiac death; ST  stent thrombosis.brin (49.3  30.8% vs. 22.3  17.8%, p  0.0005). The
ercentage of endothelialized stent struts was significantly
igher in BMS compared with DES (89.8 20.9% vs. 55.8
26.5%, p  0.0001). Regardless of implant duration,
MS stents showed significantly greater endothelialization
han DES (Fig. 2).
orphometric characteristics of DES with LST versus
atent DES. Implant duration in DES with LST was no
ifferent from patent DES (197  139 days vs. 181  135
ays, respectively, p  ns) (Table 2). The internal elastic
amina and stent area were also similar among groups,
hereas plaque area was significantly larger in cases with
ST (9.6  4.0 mm2 vs. 5.8  3.5 mm2, p  0.008). The
ean number of stents per patient was significantly
igher in patients with LST versus those with patent
tents (1.74  0.86 vs. 1.25  0.70, p  0.04), as was
tent length (38.8  18.1 mm vs. 23.6  12.2 mm, p 
.009). Signs of delayed healing were also significantly
reater in thrombosed DES with increased fibrin score
3.0  0.9% vs. 1.9  1.1%, p  0.03) and less
s) Thrombosis Versus Patent Stents (No Thrombosis)
ent
ngth
m)
Mean No.
of Stents/
Patient
Stent
Area
(mm2)
Fibrin
Score
% Struts
Endothelialized
 18.1 1.74  0.86 6.9  2.5 3.0  0.9 27.1  25.9
 12.2 1.25  0.70 6.1  3.0 1.9  1.1 66.1  25.4
09* 0.04* ns 0.03* 0.001
ther Than Delayed Stent Healing
f
s
Stent
Length
(mm)
Time
to ST
(days)
Presentation/
Cause of Death Thrombosis
ronic Inflammation (Hypersensitivity)
76 200 SCD Occlusive
27 504 AMI/rupture Occlusive*
18 112 SCD Nonocclusive
 Penetration of Necrotic Core
56 40 AMI Occlusive
Ostial and/or Bifurcation Stenting
36 450 SCD Occlusive
25, 20 172 AMI Occlusive
32 278 SCD Occlusive
alapposition/Incomplete Apposition¶
40 130 SCD Nonocclusive
32 278 SCD Occlusive
Healing  Restenosis
18 120 AMI Nonocclusive
47 112 SCD Nonocclusive
tenting LCX/LOM; §ostial stenting LAD/left diagonal; ostial stenting LAD/leftDay
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July 4, 2006:193–202 Pathology of Drug-Eluting Stentsndothelial coverage of stent struts (27.1  25.9% vs.
6.1  25.4%, p  0.001).
ntiplatelet therapy in cases of late DES thrombosis. Of
he 14 patients with LST, maintenance on dual antiplatelet
herapy (i.e., aspirin and clopidogrel) could be confirmed in
patients. An additional 2 patients were either on aspirin or
lopidogrel monotherapy. Five of 14 patients with evidence
f LST were not receiving any antiplatelet therapy at the
ime of death. In the two cases of LST after BMS
mplantation, dual antiplatelet therapy was administered for
nly 1 month and patients were on aspirin monotherapy at
he time point of death.
athologic mechanisms of DES LST. In all 14 patients
ith LST delayed arterial healing was found as a cardinal
isk factor and was the only pathologic risk factor in 3 (21%)
atients. Additional pathologic risk factors for LST were
ound in 11 of the 14 patients (Table 3). They were grouped
nto five major categories: 1) chronic inflammation charac-
erized by lymphocytes, macrophages, and extensive eosin-
philic infiltration of the intima and media (hypersensitiv-
ty) (n  3); 2) stenting along major side branches using the
igure 3. Mechanisms of late stent thrombosis in ostial and bifurcation ste
77-year-old man who had two stents placed in the native left anterior des
eath. (A) Radiograph of the LAD with two stents in place, a proximal C
nto the ostium of the left circumflex artery (LCx). (B) Section taken from
hile distally it is patent (C) with minimal neointimal tissue. The NIR ste
eointimal tissue composed of smooth muscle cells in a proteoglycan/collag
Movat pentachrome) from a 68-year-old black woman with a history of s
Taxus to LCx and Cypher to LOM) 172 days before death. She presented
atheterization laboratory, where 90% occlusion of the LCx near the LOM
he patient died of complications shortly thereafter. (E) Cypher struts wit
ections taken proximal to the bifurcation (F) and at the LCx/LOM bifur
s covered by neointimal growth. Two struts with overlying thrombus are sh
truts with overlying thrombus.rush technique and/or stenting over major branch points (n s3) (Fig. 3); 3) malapposition refers to arterial wall
xpansion (positive remodeling) late after stent deployment
6 months) or incomplete apposition caused by subopti-
al stent deployment (n 2) (Fig. 4); 4) in-stent restenosis
n  2) with superimposed thrombosis; and 5) struts
enetration of necrotic core (n  1). In comparison, in the
patients with BMS the cause of LST was in-stent
estenosis.
rterial healing Cypher versus Taxus versus BMS. His-
ologic sections from patent DES and BMS were evaluated
t corresponding time points to assess the different patterns
f arterial healing (Figs. 5 and 6). The Cypher stents
howed greater inflammatory reaction including eosinophils
nd giant cells at 60 days, whereas Taxus stents predomi-
antly showed greater fibrin deposition and fewer inflam-
atory cells at a similar time point. At 120 days there was
ocal fibrin deposition and giant cell reaction around Cypher
tents, whereas Taxus stents showed greater inflammation
onsisting of lymphocytes, eosinophils, and macrophages at
his time point. Fibrin deposition persisted in both Taxus
nd Cypher stents. In comparison, at 60 days BMS did not
. (A to D) Radiograph and histologic sections (Movat pentachrome) from
g coronary artery (LAD) for stable angina 450 days before sudden cardiac
and a distal bare-metal stent (NIR). The Cypher stent struts (*) protrude
oximal Cypher stent, which is totally occluded by a platelet-rich thrombus
) in the distal LAD demonstrates 50% in-stent area stenosis consisting of
atrix with absence of fibrin. (E to H) Radiographs and histologic sections
g of the LCx and left obtuse marginal (LOM) using the crush technique
ys before her death with acute myocardial infarction and was taken to the
-off was found. The LCx artery was opened with balloon angioplasty, but
OM and fracture of the Taxus stent after the LOM take-off. Histologic
(G) show thrombus (Th) in the LCx (Taxus), whereas the Cypher stent
at high power in H. Note the absence of neointimal coverage of the Taxusnting
cendin
ypher
the pr
nt (D
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Pathology of Drug-Eluting Stents July 4, 2006:193–202overage of stent struts was seen. Giant cell reaction and
nflammation was substantially less in the BMS examined.
he 120-day BMS showed circumferential neointimal
rowth with complete coverage of stent struts. Chronic
nflammatory cells (mostly lymphocytes, macrophages, and
iant cells) are commonly seen in BMS at this time point
ut without evidence of eosinophilic infiltrate.
ISCUSSION
he pathologic findings of our study underscore the causal
elationship between the two currently FDA-approved
ES and delayed arterial healing. The persistence of fibrin
nd incomplete endothelialization far beyond 30 days from
he time of stenting form the critical pathologic substrate
nderlying the phenomenon of LST. These partially endo-
helialized, fibrin-rich sites remain a potent thrombogenic
timulus. In high-risk clinical situations such as bifurcation
tenting, excessive stent length, or cessation of antiplatelet
herapy, these sites may develop thrombosis, leading to
eath or other serious consequences.
istologic findings >30 days. In patients suffering from
ST after DES placement, the major pathologic finding
istinguishing thrombosed from patent DES was evidence
f significantly greater delay in arterial healing as manifested
y persistent peristrut fibrin deposition and poor endothe-
ialization. In contrast, the control group of BMS implants
igure 4. Histologic sections of the stented artery from a 38-year-old woma
rtery (LAD) with a 3.0  12-mm Taxus stent 6 months before death.
mergency room with severe chest pain and shortly thereafter went into ve
roximal and middle sections of the stented LAD stained with Movat pent
f the lumen by platelet-rich thrombus (Th) with absence of healing of th
he orifice of the diagonal branch. High-power view of the stent struts in
ndothelial, and inflammatory cells.howed greater neointimal healing with very little peristrut ibrin and near complete endothelialization consistent with
arlier pathologic studies of BMS, which have suggested
ear-complete endothelialization by 3 to 4 months (19,20).
hroughout a wide range of time points examined, BMS
onsistently showed evidence of greater healing when com-
ared with DES.
echanisms of delayed arterial healing. The mechanisms
y which DES cause a prolongation of arterial healing in
umans are poorly understood. Although sirolimus or
aclitaxel reduce neointimal formation by impeding smooth
uscle cell proliferation and migration, these drugs also
mpair the normal healing processes of the injured arterial
all (21–23). Animal studies using healthy pigs have shown
ersistence of fibrin at 28 days, however, endothelialization
as similar between DES and BMS (9). Also, it is well
nown that in pig coronary arteries endothelialization after
MS implantation may be80% by 7 days and that healing
akes longer in humans as compared with normal animal
oronary arteries (24). Moreover, rates of endothelialization
fter stent implantation seem to vary among currently used
nimal models. Although experience from porcine coronary
mplants suggests complete endothelialization 28 days after
tent deployment (11), our own data of rabbit iliac implants
ndicate a clear delay of endothelialization in sirolimus- and
aclitaxel-eluting stents (13).
Because of the small number of stents examined, it is
o had undergone stenting of the proximal left anterior descending coronary
atient had been taking clopidogrel and aspirin, but presented to a local
lar fibrillation and died. (A) Radiograph of the stented LAD. (B and C)
me and hematoxylin and eosin (HE), respectively. There is total occlusion
t strut regions, which are surrounded by fibrin. The stent is placed across
ovat) and E (HE) show peristrut fibrin with absence of smooth muscle,n wh
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July 4, 2006:193–202 Pathology of Drug-Eluting Stentsbout the selective effects of each type of drug/stent com-
ination on arterial wall healing in humans. Coronary
egments implanted with either type of DES showed
elayed healing when compared with BMS.
Both the Cypher and Taxus stents allow the selective
elease and binding of drug that significantly influences
rterial wall concentration and distribution responsible for
ocal pharmacologic effects (25). For example, Cypher stents
lute nearly all of the loaded sirolimus by 30 days from a
olyethylene-co-vinyl acetate and poly n-butyl methacrylate
on-erodable polymer (10,26). In contrast, Taxus stents
elease paclitaxel as a initial burst from poly(styrene-b-
sobutylene-b-styrene) polymer followed by a constant slow
elease up to 90 days (R. Virmani, unpublished data, April
005).
The thrombus as well as lipid within the stented athero-
clerotic plaque may also influence drug distribution and
etention (27). Previous data regarding drug levels of siroli-
us and paclitaxel delivered on stents have been generated
n normal animals (10,26), and given the hydrophobic
ature of both compounds it is unclear whether atheroscle-
osis prolongs tissue retention leading to long-term biolog-
cal effects.
athologic correlates: late thrombosis is likely multifac-
orial in causality. Although the degree of arterial healing
as significantly less in thrombosed DES sections, stent length
igure 5. Histologic sections stained with hematoxylin and eosin (HE) fro
ime points. Coronary arteries with Cypher (A) and Taxus (B) stents at 6
round Cypher struts (C) including eosinophils (inset Luna stain), where
nd 124 days, respectively, there is focal fibrin deposition and giant cell re
s greater inflammation including eosinophils (inset Luna stain). A BMSas significantly greater. A governing principle in the deploy- sent of DES has been to effectively treat the entire lesion
28,29). This dictum has led to the use of longer stents.
The findings of this study support prior clinical observa-
ions that the risk of stent thrombosis after DES placements
s related to stent length (29,30). As stent length increases,
t may be more difficult to ensure complete deployment
30,31), causing a predispositon toward thrombosis by
reating abnormal shear stress (32,33) at malapposed or
ncompletely apposed stent struts. Malapposition/incomplete
pposition was observed in 2 of 14 cases and thus represents
n additional risk factor for LST. This is consistent with
ntravascular ultrasound studies that have shown that stent
alapposition and underexpansion are significantly associ-
ted with stent thrombosis (34).
Other additional risk factors that predispose toward late
hrombosis include local arterial hypersensitivity reactions as
videnced by eosinophils, which may be secondary to
olymer (15). Further, penetration of a necrotic core by
tent struts, crossing branch points, or bifurcation stenting
re additional risk factors for late DES thrombosis as occurs
ith BMS (19,35). Breaching a necrotic core may lead to
he exposure of thrombogenic lipid content to flowing
lood. Arterial branch points may also predispose towards
hrombosis by inducing flow disturbances and changes in
hear stress (35,36). Withdrawal of aspirin and/or clopi-
ogrel therapy has previously been reported to be a very
ent drug-eluting stents (DES) and bare-metal stents (BMS) from various
57 days, respectively. High-power views showing inflammatory infiltrate
und the Taxus stent struts (D) there is a predominance of fibrin. At 130
seen around the Cypher stent (E), whereas in the Taxus stent (F) there
4 days is shown in G and H.m pat
8 and
as aro
actionignificant risk factor for LST with DES. It is not surprising
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Pathology of Drug-Eluting Stents July 4, 2006:193–202hat poorly healed sites of DES placement pose a significant
isk for complete thrombosis when antiplatelet therapy is
bruptly discontinued.
ate thrombosis: clinical correlates. The true incidence of
ES LST is unknown. The reported rates of LST vary
rom 0.23% to 0.7% (7,29,37). Complicating the interpre-
ation of these data are the differing definitions of LST
clinical vs. angiographic), the differing duration of anti-
latelet therapy, the types of lesions stented, and duration of
ollow-up. The increasing use of DES for a wide variety of
linical and anatomic situations such as bifurcation stenting,
verlapping stent deployment, or acute myocardial infarc-
ion, most of which have not been evaluated in randomized
tudies, means that the reported incidence of DES LST in
hese trials may not reflect the real-world incidence.
It is difficult to compare the incidence of DES LST with
hat from the BMS era because of the complicating issues of
estenosis with superimposed thrombosis, prior brachyther-
py treatment, and differing duration and type of antiplate-
et therapy used. The reported incidence of late thrombosis
igure 6. A 65-year-old man suffered traumatic injury to the head resultin
oronary artery (LAD), a proximal Cypher and a distal Bx Velocity 15 mo
(Bx Velocity) are radiographs of the stented LAD segment. All section
he Cypher stented artery showing minimal coverage of the struts by fibrin
ells but no luminal thrombus, whereas inflammation and smooth muscle
bundant neointimal tissue consisting of smooth muscle cells in a proteogl
he boxed area in E. Lymphocytes are present around the stent strut with
y smooth muscle cells in a proteoglycan/collagen rich matrix.or BMS varies from 0.6% to 0.8% (19,38,39). However, nMS do not cause the same degree of delay in arterial
ealing seen with the two currently FDA-approved DES.
Regardless of the true incidence, the consequences of
ES LST are dire. Iakovou et al. (7) reported a 45% rate of
eath for patients suffering DES LST, with the majority of
thers suffering nonfatal myocardial infarction. This lethal-
ty is substantially higher than the reported 16.7% to 20.8%
atality rate for BMS LST, and in part may reflect the
endency to perform more complex multiterritory revascu-
arization in the DES era (30,38). This study shows that
ven 6 to 7 months after implantation of Cypher and Taxus
ES, these sites are not completely endothelialized in the
atients studied in this report. Therefore, it remains uncer-
ain at what time point after stenting the patients can safely
e taken off of antiplatelet therapy.
tudy limitations. Because this is an autopsy study, the
esults presented may not be representative of persons who
eceive DES and survive. Also, a large number of patients in
his study received DES stents for non–FDA-approved
ndications such as acute myocardial infarction, and so may
eath. This patient had received two stents in the left anterior descending
before death, which were found to be patent at autopsy. A (Cypher) and
n have been stained with Movat pentachrome. (B) Histologic section of
High-power magnification showing peristrut fibrin with rare endothelial
are only rarely observed. (E) Section of the Bx Velocity stent. There is
collagen matrix and an overlying endothelium. (F) High-power section of
al fibrin underneath the strut. The luminal surface of the stent is coveredg in d
nths
s show
. (C)
cells
ycan
minimot reflect the arterial pathologic changes that occur when
t
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July 4, 2006:193–202 Pathology of Drug-Eluting Stentshese stents are placed only for approved uses. In the present
tudy, however, a large number of stents were analyzed in
ndividuals who did and did not suffer stent-associated
orbidity, and it is likely that the results reported here are
pplicable to patients receiving DES.
onclusions. This is the first published study to examine
ystematically the effects of the two currently FDA-approved
ES on human coronary pathology. Both DES caused a
ignificant delay in arterial healing characterized by persistent
brin deposition and delayed re-endothelialization when
ompared with sites of BMS implantation. The cause of
ES LST is likely multifactorial, with delayed healing in
ombination with other clinical and/or procedural risk
actors such as withdrawal of antiplatelet therapy, malappo-
ition/incomplete apposition, and bifurcation stenting play-
ng an important role. Because the time course of arterial
ealing after Cypher or Taxus DES placement may vary
rom patient to patient, all patients at high risk for late
hrombosis should receive dual antiplatelet therapy with
spirin and clopidogrel for prolonged periods of time.
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